BLFS

BioLife Solutions

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Medical Instruments & Supplies

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/14/26

Business Summary

BioLife Solutions operates in the high-value niche of biopreservation tools and services, supplying cold chain management and storage solutions critical to cell and gene therapies. Its cash generation model is tied to recurring demand from biotechnology and pharmaceutical clients that require validated, compliant preservation systems for sensitive biologic materials. The moat is built around regulatory integration, product reliability, and embedded positioning within customers’ clinical and commercial workflows, making switching costs meaningful once adopted. As advanced therapies scale, the company benefits from being infrastructure rather than a discretionary supplier, anchoring it to long-term growth in regenerative medicine.

VALUATION

P/E

-

Market Cap ($M USD)

$953

Forward P/E

68.1

PEG

0.8

PRICE TO SALES

10

PRICE TO BOOK

2.6

EV / EBITDA

-74

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.25

Next Year EPS Growth Estimate

$0.29

Next Year Revenue Growth Estimate

18.80%

Return on Equity (ROE)

-1.20%

Operating Margin

-17.30%

Debt-to-Equity

0.1

Piotroski F-Score

6

Altman Z-Score

16.1

Return on Invested Capital (ROIC)

-1.20%%

Current Ratio

5.9

Quick Ratio

Gainseekers Quantitative Analysis

Summary

This is a speculative growth story wrapped in a fragile income statement but backed by fortress-level balance sheet safety. A Forward P/E of 68.1 is expensive on the surface, yet the PEG Forward of 0.8 suggests the market is discounting a meaningful earnings inflection relative to growth expectations. The Altman Z-Score of 16.1 and a Current Ratio of 5.9 signal extremely low bankruptcy risk and ample liquidity, which offsets the negative EPS of -74 and Operating Margin of -1.20%. With a $953M market cap and Price/Sales of 10, investors are clearly paying for future scalability rather than present profitability, making this a high-risk GARP setup rather than a deep value play.

AI Exposure / Tech Reliance

Operating in Medical Instruments & Supplies within Healthcare, the company sits in a segment that increasingly benefits from automation, data integration, and AI-driven logistics optimization. As biologics and advanced therapies scale, technology-enhanced storage, preservation, and supply chain solutions become mission-critical infrastructure rather than optional tools. This industry positioning gives it structural relevance in a tech-forward healthcare ecosystem.

The Bull Case

A disciplined GARP investor could justify ownership based on improving fundamentals and balance sheet strength. The Piotroski F-Score of 6 signals moderate financial stability and operational consistency, while Return on Equity of 18.80% demonstrates the ability to generate meaningful returns on shareholder capital despite current earnings pressure. The PEG Forward of 0.8 implies growth is reasonably priced relative to forward expectations, and the Altman Z-Score of 16.1 combined with a 5.9 Current Ratio dramatically reduces solvency risk. Institutional Ownership at 32.67% indicates credible smart-money participation, and a ROIC of -1.20% paired with an Operating Margin of -1.20% suggests the company is near breakeven, meaning even modest operating leverage could materially swing profitability.

The Bear Case

The bear case is straightforward: this company is not currently profitable, with EPS at -74 and Operating Margin at -1.20%, yet it trades at a rich Forward P/E of 68.1 and Price/Sales of 10. That valuation leaves no room for execution missteps. ROIC at -1.20% indicates capital is not yet generating positive economic returns, and the absence of a meaningful dividend profile removes any income cushion. The Debt/Equity of -17.30% is unconventional and suggests a capital structure dynamic that may distort traditional leverage analysis, while a Mean Consensus Target Price of 1 raises serious questions about upside visibility relative to current valuation.

Market Sentiment & Smart Money

Short Interest %

9.10%

Analyst Consensus

1

Average Analyst Price Target

$32.67

Institutional Ownership %

106.40%

1-Year Beta

1.64

Insider Buying % (6 Mo)

2.60%%

Distance to 52-Week High

66.60%%

Distance to 52-Week Low

110.50%%